Terms: = Lymphoma AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
60 results:
1. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
2. Serum TK1 protein and C-reactive protein correlate to treatment response and predict survival in dogs with hematologic malignancies.
Saellström S; Sharif H; Jagarlamudi KK; Rönnberg H; Wang L; Eriksson S
Res Vet Sci; 2022 Jul; 145():213-221. PubMed ID: 35245727
[TBL] [Abstract] [Full Text] [Related]
3. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Dekker L; Calkoen FG; Jiang Y; Blok H; Veldkamp SR; De Koning C; Spoon M; Admiraal R; Hoogerbrugge P; Vormoor B; Vormoor HJ; Visscher H; Bierings M; Van Der Vlugt M; Van Tinteren H; Nijstad AL; Huitema ADR; Van Der Elst KCM; Pieters R; Lindemans CA; Nierkens S
Blood Adv; 2022 Apr; 6(7):1969-1976. PubMed ID: 35134115
[TBL] [Abstract] [Full Text] [Related]
4. HELICOBACTER PYLORI cagA VIRULENCE GENE AND SEVERE ESOGASTRODUODENAL DISEASES: IS THERE AN ASSOCIATION?
Oliveira AKS; Silva LLL; Miguel MP; Blanco AJV; Carneiro LC; Barbosa MS
Arq Gastroenterol; 2021; 58(4):468-475. PubMed ID: 34909852
[TBL] [Abstract] [Full Text] [Related]
5. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
Badar T; Szabo A; Litzow M; Burkart M; Yurkiewicz I; Dinner S; Hefazi M; Shallis RM; Podoltsev N; Patel AA; Curran E; Wadleigh M; Balasubramanian S; Yang J; Arslan S; Aldoss I; Mattison R; Cenin D; Siebenaller C; Advani A; Liedtke M; Atallah E
Bone Marrow Transplant; 2021 Aug; 56(8):1998-2004. PubMed ID: 33824440
[TBL] [Abstract] [Full Text] [Related]
6. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract] [Full Text] [Related]
7. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
Qu X; Li H; Braziel RM; Passerini V; Rimsza LM; Hsi ED; Leonard JP; Smith SM; Kridel R; Press O; Weigert O; LeBlanc M; Friedberg JW; Fang M
Blood; 2019 Jan; 133(1):81-93. PubMed ID: 30446494
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy.
Lee J; Shishido-Hara Y; Suzuki K; Shimizu S; Kobayashi K; Kamma H; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2017 Oct; 47(10):925-934. PubMed ID: 28981733
[TBL] [Abstract] [Full Text] [Related]
9. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract] [Full Text] [Related]
10. Beta-2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Hematol Oncol; 2017 Dec; 35(4):440-446. PubMed ID: 27238634
[TBL] [Abstract] [Full Text] [Related]
11. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract] [Full Text] [Related]
12. The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma.
Tsai HT; Pfeiffer RM; Warren J; Wilson W; Landgren O
Leuk Lymphoma; 2015 Mar; 56(3):682-7. PubMed ID: 24893799
[TBL] [Abstract] [Full Text] [Related]
13. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell lymphoma Network.
Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
[TBL] [Abstract] [Full Text] [Related]
14. The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era.
Nabhan C; Aschebrook-Kilfoy B; Chiu BC; Smith SM; Shanafelt TD; Evens AM; Kay NE
Leuk Lymphoma; 2014 Dec; 55(12):2778-84. PubMed ID: 24588735
[TBL] [Abstract] [Full Text] [Related]
15. clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
Gojo I; Sadowska M; Walker A; Feldman EJ; Iyer SP; Baer MR; Sausville EA; Lapidus RG; Zhang D; Zhu Y; Jou YM; Poon J; Small K; Bannerji R
Cancer Chemother Pharmacol; 2013 Oct; 72(4):897-908. PubMed ID: 23949430
[TBL] [Abstract] [Full Text] [Related]
16. clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract] [Full Text] [Related]
17. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.
Baig NA; Taylor RP; Lindorfer MA; Church AK; Laplant BR; Pavey ES; Nowakowski GS; Zent CS
Leuk Lymphoma; 2012 Nov; 53(11):2218-27. PubMed ID: 22475085
[TBL] [Abstract] [Full Text] [Related]
18. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE
J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152
[TBL] [Abstract] [Full Text] [Related]
19. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
[TBL] [Abstract] [Full Text] [Related]
20. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
[TBL] [Abstract] [Full Text] [Related]
[Next]
